Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Sim Mei Yi

4PUBLICATIONS
2CO-AUTHORS
Molecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

Sort by Publication Date:
|Nov 03, 2021
Author Correction: PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein.

Min Thura, Abdul Qader Al-Aidaroos, Abhishek Gupta

|Jun 08, 2019
PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein.

Min Thura, Abdul Qader Al-Aidaroos, Abhishek Gupta

|Jul 08, 2018
Anti-survivin effect of the small molecule inhibitor YM155 in RCC cells is mediated by time-dependent inhibition of the NF-κB pathway.

Mei Yi Sim, John Shyi Peng Yuen, Mei Lin Go

|Jun 06, 2017
Action of YM155 on clear cell renal cell carcinoma does not depend on survivin expression levels.

Mei Yi Sim, Hung Huynh, Mei Lin Go

Pageof 1

Frequent Collaborators

2 joint publications

Abdul Qader Al-Aidaroos

2 joint publications

Jianbiao Zhou

Frequent Collaborators

2 joint publications

Abdul Qader Al-Aidaroos

2 joint publications

Jianbiao Zhou

Top Related Videos

Tractable <em>In Vivo</em> Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable <em>In Vivo</em> Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on : Aug 01, 2025

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on : Feb 24, 2023

3.9K
Identification of Mediators of T-cell Receptor Signaling <em>via</em> the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling <em>via</em> the Screening of Chemical Inhibitor Libraries

Published on : Jan 22, 2019

9.6K
See more related videos

Top Related Videos

Tractable <em>In Vivo</em> Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable <em>In Vivo</em> Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on : Aug 01, 2025

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on : Feb 24, 2023

3.9K
Identification of Mediators of T-cell Receptor Signaling <em>via</em> the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling <em>via</em> the Screening of Chemical Inhibitor Libraries

Published on : Jan 22, 2019

9.6K
See more related videos